BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu RF, Gao YL, Robert SH, Gao JP, Yang SG, Zhu CT. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19). J Transl Med 2020;18:274. [PMID: 32631442 DOI: 10.1186/s12967-020-02442-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Kudhail K, Thompson J, Mathews V, Morrison B, Hemming K. Randomized controlled trials in patients with COVID-19: a systematic review and critical appraisal. Int J Infect Dis 2022;122:72-80. [PMID: 35597556 DOI: 10.1016/j.ijid.2022.05.034] [Reference Citation Analysis]
2 Ahmed FF, Reza MS, Sarker MS, Islam MS, Mosharaf MP, Hasan S, Mollah MNH. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches. PLoS One 2022;17:e0266124. [PMID: 35390032 DOI: 10.1371/journal.pone.0266124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Mosharaf MP, Reza MS, Kibria MK, Ahmed FF, Kabir MH, Hasan S, Mollah MNH. Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing. Sci Rep 2022;12:4279. [PMID: 35277538 DOI: 10.1038/s41598-022-08073-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
4 Hussain M, Khurram Syed S, Fatima M, Shaukat S, Saadullah M, Alqahtani AM, Alqahtani T, Bin Emran T, Alamri AH, Barkat MQ, Wu X. Acute Respiratory Distress Syndrome and COVID-19: A Literature Review. J Inflamm Res 2021;14:7225-42. [PMID: 34992415 DOI: 10.2147/JIR.S334043] [Reference Citation Analysis]
5 Srinivasan K, Rao M. Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review. Ther Adv Infect Dis 2021;8:20499361211063016. [PMID: 34881025 DOI: 10.1177/20499361211063016] [Reference Citation Analysis]
6 Speich B, Chammartin F, Smith D, Stoeckle MP, Amico P, Eichenberger AL, Hasse B, Schuurmans MM, Müller T, Tamm M, Dickenmann M, Abela IA, Trkola A, Hirsch HH, Manuel O, Cavassini M, Hemkens LG, Briel M, Mueller NJ, Rauch A, Günthard HF, Koller MT, Bucher HC, Kusejko K; study groups from the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. Trials 2021;22:724. [PMID: 34674742 DOI: 10.1186/s13063-021-05664-0] [Reference Citation Analysis]
7 Qazi S, Das S, Khuntia BK, Sharma V, Sharma S, Sharma G, Raza K. In Silico Molecular Docking and Molecular Dynamic Simulation Analysis of Phytochemicals From Indian Foods as Potential Inhibitors of SARS-CoV-2 RdRp and 3CLpro. Natural Product Communications 2021;16:1934578X2110317. [DOI: 10.1177/1934578x211031707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kurd R, Freed Y, Jarjoui A, Izbicki G, Levin P, Helvitz Y, Sherr J, Oberbaum M. Homeopathic Treatment for COVID-19-Related Symptoms: A Case Series. Complement Med Res 2021;:1-6. [PMID: 34521083 DOI: 10.1159/000517924] [Reference Citation Analysis]
9 Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev 2021;9:CD013825. [PMID: 34473343 DOI: 10.1002/14651858.CD013825.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
10 Honarmand K, Penn J, Agarwal A, Siemieniuk R, Brignardello-Petersen R, Bartoszko JJ, Zeraatkar D, Agoritsas T, Burns K, Fernando SM, Foroutan F, Ge L, Lamontagne F, Jimenez-Mora MA, Murthy S, Yepes-Nuñez JJ, Vandvik PO, Ye Z, Rochwerg B. Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. J Clin Epidemiol 2021;139:68-79. [PMID: 34274489 DOI: 10.1016/j.jclinepi.2021.07.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Hailat M, Al-Ani I, Hamad M, Zakareia Z, Abu Dayyih W. Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma. Molecules 2021;26:3789. [PMID: 34206357 DOI: 10.3390/molecules26133789] [Reference Citation Analysis]
12 Gashaw T, Hagos B, Sisay M. Expected Impacts of COVID-19: Considering Resource-Limited Countries and Vulnerable Population. Front Public Health 2021;9:614789. [PMID: 34026704 DOI: 10.3389/fpubh.2021.614789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 He Z, Erdengasileng A, Luo X, Xing A, Charness N, Bian J. How the clinical research community responded to the COVID-19 pandemic: an analysis of the COVID-19 clinical studies in ClinicalTrials.gov. JAMIA Open 2021;4:ooab032. [PMID: 34056559 DOI: 10.1093/jamiaopen/ooab032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Li X, Zhang S, Zhou Y, Liu Y, Zhou Y, Li S, Su N. Deficiencies in Planning Interventional Trial Registration of COVID-19 in China. Front Med (Lausanne) 2021;8:618185. [PMID: 33869242 DOI: 10.3389/fmed.2021.618185] [Reference Citation Analysis]
15 Almufleh A, Joseph J. The time is now: role of pragmatic clinical trials in guiding response to global pandemics. Trials 2021;22:229. [PMID: 33761968 DOI: 10.1186/s13063-021-05165-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhao MZ, Zhao C, Tu SS, Wei XX, Shang HC. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. J Integr Med 2021;19:317-26. [PMID: 33789839 DOI: 10.1016/j.joim.2021.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Pérez de la Lastra JM, Andrés-juan C, Plou FJ, Pérez-lebeña E. Impact of Zinc, Glutathione, and Polyphenols as Antioxidants in the Immune Response against SARS-CoV-2. Processes 2021;9:506. [DOI: 10.3390/pr9030506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
18 Luo X, Liu Y, Ren M, Zhang X, Janne E, Lv M, Wang Q, Song Y, Mathew JL, Ahn HS, Lee MS, Chen Y. Consistency of recommendations and methodological quality of guidelines for the diagnosis and treatment of COVID-19. J Evid Based Med 2021;14:40-55. [PMID: 33565225 DOI: 10.1111/jebm.12419] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
19 Biţă A, Scorei IR, Mogoantă L, Bejenaru C, Mogoşanu GD, Bejenaru LE. Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment. Rom J Morphol Embryol 2020;61:321-34. [PMID: 33544784 DOI: 10.47162/RJME.61.2.02] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J 2021;23:14. [PMID: 33400058 DOI: 10.1208/s12248-020-00532-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
21 Wu Y, Li Z, Zhao YS, Huang YY, Jiang MY, Luo HB. Therapeutic targets and potential agents for the treatment of COVID-19. Med Res Rev 2021;41:1775-97. [PMID: 33393116 DOI: 10.1002/med.21776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
22 Padmanabhan P, Desikan R, Dixit NM. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection. PLoS Comput Biol 2020;16:e1008461. [PMID: 33290397 DOI: 10.1371/journal.pcbi.1008461] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
23 Bhapkar V, Sawant T, Bhalerao S. A critical analysis of CTRI registered AYUSH studies for COVID- 19. J Ayurveda Integr Med 2020:S0975-9476(20)30103-0. [PMID: 33262559 DOI: 10.1016/j.jaim.2020.10.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
24 Angurana SK, Bansal A. Probiotics and Coronavirus disease 2019: think about the link. Br J Nutr 2020;:1-7. [PMID: 32921328 DOI: 10.1017/S000711452000361X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]